Gt Biopharma, Inc. · NASDAQ:GTBP
Gt Biopharma — Investor Day (May 2021)
18 slides from Gt Biopharma's investor day presentation, May 19, 2021
Slide 1: GT Biopharma Investor Day May 19, 2021
GT BIOPHARMA Clinical Stage Company NASDAQ: GTBP INVESTOR DAY MAY 19, 2021 Non Content
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT ‘This presentation includes statements that ae of may be deemed, “forward ooking statement n some cases, you can entity forward ooking statements by tecmnolgy inlaing“antipates” “Debeves “an” “eontnue” “could” eslimates” “expects” “end” “may” “land” “potential” “predets” “s
Slide 3: Company Focus — Harnessing Patient NK Cells to Fight Cancer
Company Focus — HARNESSING PATIENT NK CELLS To FIGHT CANCER Restore patient’s exhausted/inhibited endogenous NK cell population to again recognize and kill cancer cells. Integrate targeted CD16 activation and IL-15 cytokine support in a single therapeutic to drive: > Endogenous NK cell activation an
Slide 4: What Is a TriKE Therapeutic?
WHAT IS A TRIKE™ THERAPEUTIC? i donm P- anti-cors = 1S Uinker Cancer Cll Binder cancer call Torget ha Key Therapeutic Features: (tren by it rca Nc (un. + Target-directed ADCC killing, + Integrated cytokine support within the tumor micro-environment (TME). + Simultaneous NK cell ADCC activation, prol
Slide 5: Product Candidate Highlights
GTB-3550 TRIKE™ PRODUCT CANDIDATE HIGHLIGHTS First-in-Class Immuno-Oncology Therapeutic. Up to 63.7% Reduction in Bone Marrow Blast Levels seen in some patients. Restoration of Patient’s Endogenous NK Cell Function, Proliferation and Immune Surveillance. No Progenitor-derived or Autologous/Allogenic
Slide 6: First-in-Human Clinical Trial Design
GTB-3550 TRIKE™ FirST-IN-HUMAN CLINICAL TRIAL DESIGN hose 1 Schedule AAA = 2.3 Week Rest Between Cycle #1 ond Cycle #2 Phase 1: Safety and RP2D Determination Patients will eceive GTB-2550 atthe assigned dose level Patients ‘will receive GTB-3550 atthe asigned dose for three consecutive ‘weekly 96 ho
Slide 7: First-in-Human Clinical Trial Interim Results
GTB-3550 TRIKE™ FIRST-IN-HUMAN CLINICAL TRIAL INTERIM RESULTS Clinical Efficacy Demonstrat * Patient 5: 33.3% Reduction in Blast Levels * Patient 7: 61.7% Reduction in Blast Levels * Patient 9: 63.6% Reduction in Blast Levels
Slide 8: Well Tolerated by Patients
GTB-3550 TRIKE™ Is WELL TOLERATED BY PATIENTS one! A: Dose Equivalent of GTB-2550 and Systemic Maximum Panel: Systolic Blood Pressure TherapeutieDose of LS,
Slide 9: Clinical Trial Immune Monitoring Results
GTB-3550 TRIKE™ CLINICAL TRIAL IMMUNE MONITORING RESULTS ancl: cress Kel acaton vp sna of 6.3550. ate cress nasser of NK ca ing ese aac Seria Xcel proeaton by ay wth continvd peterson wall above etn dgurestmert eu
Slide 10: Clinical Trial Immune Monitoring Results
GTB-3550 TRIKE™ CLINICAL TRIAL IMMUNE MONITORING RESULTS No Hyperactivation of T-cells 100. 100. © Sunk cs & 10u9k9 8 oo. 8 eo. se 25ugkg Fa ¢ © S0ugk9 g« g « Fd Fa 2 2 ° °. pre day3 day8 day 18 day22 pre day day day 18 day 22 Geren Non Confident
Slide 11: Clinical Trial Immune Monitoring Results
GTB-3550 TRIKE™ CLINICAL TRIAL IMMUNE MONITORING RESULTS No Loss of CD16 During GTB-3550 Therapy nee pay 1s Day 22 Day 29 é a { y g 1 Separates 3 |sgy costo 8 ial + | # and cOS6dm core - ernss0 heeey ‘aston Data from patient #7 treated with 50 mcg/kg/day
Slide 12: Clinical Trial Immune Monitoring Results
GTB-3550 TRIKE™ CLINICAL TRIAL IMMUNE MONITORING RESULTS TriKE Therapy Rescues Patient’s NK Cells & Increases Cancer Cell Killing S62 AML Cancer Cells + Patient’s NK Cells HL60 AML Cancer Cells + Patient’s NK Cells From patient #7 treated at 50 meg/kg patient Lysis Measured in Standard 4 hr Chromium
Slide 13: Clinical Trial Interim Results Summary
GTB-3550 TRIKE™ CLINICAL TRIAL INTERIM RESULTS SUMMARY + GTB-3550 TriKE induces reproducible NK cell proliferation in all patients at all dose levels evaluated with no clinically significant toxicity. No CRS resulting from hyperactivation of patient’s T-cell population. * Clinical responses to date
Slide 14: NK Cell Infiltration of Tumor Improves Patient Survival
NK CELL INFILTRATION OF TUMOR IMPROVES PATIENT SURVIVAL ow WK Cation Mien cet ition Aopen oe 8829-28 = High vs Low NK Cell infiltration into Tumor ge i WH nigh group (253) ae z g4 mx Low group (n=07) a 2 ° eo 1 2 3 4 6 ‘Time After Surgery (months) ‘Overall survival curves f patents with pulmonary ad
Slide 15: TriKE B7H3: Multi-Cancer Strategy
TRIKE™ B7H3: MULTI-CANCER STRATEGY Day 21 After MA-148 Tumor Implant Aas rv 7] Tumor NK+ 1L15 A Ay Was ww NK + Be] & : TriKE™ B7H3 [A j Dosing: Sx/week (MTWTHF) Schedule: 3 weeks wae ina a ar i En. ey zw car | antl a) ea Milit tilly AF ? ff riKE™ B7H3
Slide 16: TriKE Product Candidate Pipeline
TRIKE™ PRODUCT CANDIDATE PIPELINE Anticipated Time to Next Milestone eerie > oa (Leukemia AML, MOS and other CO33e End of Phase Cancers) ore-48s0 eeciTssaraeremeey —) sont ore-s8s0 (2 td Tamer Caner —) son ore.sss0 aecee) — saat
Slide 17: Partnership Highlights
PARTNERSHIP HIGHLIGHTS C\tovance Biologics > Cytovance will develop GMP cell lines, and manufacture TriKE product candidates for use in GT Biopharma clinical trials. > GT Biopharma has the option to pay Cytovance in cash or shares of GT Biopharma common stock. > Cytovance will help develop new TrikE
Slide 18: GT Biopharma
GT BIOPHARMA Clinical Stage Company NASDAQ: GTBP INVESTOR DAY MAY 19, 2021 Non Content